Increase the anti-inflammatory effects of hyaluronic acid (HA) treatment for osteoarthritis (OA) knee pain with^2-4

Dual-Acting EUFLEXXA

Mechanical

Improves viscoelasticity,
joint lubrication, and cushioning^2-4

PHYSIOLOGIC

Disrupts the inflammatory cascade, protects cartilage, and stimulates endogenous HA production^2-5

HA Injections

Learn more about HA injections
and key characteristics that set
some apart from the rest.

See The Differences

Efficacy

Discover how EUFLEXXA performed
across three robust clinical trials.

Explore the Results

Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Cartilage. 2019;10(1):43-52.
Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disor. 2015;16:321.
Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA^® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

Important Safety Information

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.